RxDoctor Payments Data

Febbie Phiri

Family · San Antonio, TXNPI 1437818101

Payments from drug & device makers

$30,921in general payments, 2019–2025

Across 991 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Novo Nordisk$3K
  • Abbott$2K
  • Dexcom, Inc.$2K
  • Lilly USA, LLC$2K
  • Mannkind Corporation$1K
  • plus $14K from 37 others

What the payments were for

  • Travel & lodging$1,2744%
  • Food & beverage$29,64796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,921 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide429$611,628
MounjaroTirzepatide364$540,056
KorlymMifepristone12$484,079
JardianceEmpagliflozin191$276,223
TrulicityDulaglutide137$220,538
FarxigaDapagliflozin Propanediol126$141,558
AfrezzaInsulin Regular, Human42$131,652
Tresiba Flextouch U-100Insulin Degludec60$47,513
ProliaDenosumab26$45,075
Repatha SureclickEvolocumab32$31,084
Humulin R U-500 KwikpenInsulin Regular, Human16$30,883
HumalogInsulin Lispro98$30,214
Tresiba Flextouch U-200Insulin Degludec22$30,047
V-Go 30Sub-Q Insulin Device, 30 Unit58$29,048
V-Go 20Sub-Q Insulin Device, 20 Unit40$28,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro$1,995$806,719700 claims
Novo NordiskOzempic, Fiasp, Novolog$3,157$635,922463 claims
Corcept TherapeuticsKorlym$1,424$484,07912 claims
Boehringer IngelheimJardiance, Tradjenta$1,079$292,673202 claims
AstraZenecaFarxiga$1,276$141,558126 claims
Mannkind CorporationAfrezza$1,443$131,65242 claims
AmgenProlia$1,060$45,07526 claims
MerckJanuvia, Janumet Xr$57$31,27834 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$28$24,52116 claims
Cequr CorporationCequr Simplicity$741$9,96023 claims
AbbVieSynthroid$282$5,59770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →